Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Rhea-AI Summary

Scinai Immunotherapeutics (Nasdaq: SCNI), a biopharmaceutical company focused on inflammation and immunology products and CDMO services, has announced its leadership's participation in three major US healthcare conferences in January 2025. CEO Amir Reichman and Board Chairman Mark Germain will attend the IATI Mini Mixiii Conference in Miami (Jan 9), the JP Morgan HealthCare Conference in San Francisco (Jan 13-15), and the SIC Biotech Symposium in San Francisco (Jan 14).

During these events, they will meet with institutional and private investors, potential pharma partners interested in their NanoAbs technology, and prospective CDMO services clients. Interested parties can schedule meetings through the conference platforms or by contacting ir@scinai.com. The company has also released a video showcasing their 2024 achievements.

JERUSALEM, Jan. 6, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today that its CEO, Mr. Amir Reichman, and Chairman of the Board, Mr. Mark Germain, will attend the IATI Mini Mixiii Conference in Miami, FL on Jan 9, 2025 and the JP Morgan HealthCare Conference week in San Francisco from Jan 13-15, 2025. On Jan 14, 2025, Mr. Reichman and Mr. Germain will also participate in the SIC Biotech Symposium in San Francisco.

During these events, Mr. Reichman and Mr. Germain will hold meetings with:

• Institutional and private investors interested in Scinai's value proposition.
• Potential pharma partners in the inflammation & immunology field interested in co-developing or in-licensing Scinai's innovative NanoAbs.
• Prospective clients for the company's comprehensive biologics CDMO services.

Interested parties are encouraged to schedule a meeting through:

1)  The Mini Mixiii conference partnering platform

2)  The CSSi partnering system

3)  Emailing Scinai at ir@scinai.com

The company has recently released a year-end video highlighting the key accomplishments and achievements of 2024. To watch the video, please click on the following https://youtu.be/0YlY1uf5A64

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.

Company website: www.scinai.com.

Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
Business Development | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to;  lower than anticipated revenues of Scinai's CDMO business; the risk that Scinai's expanded presence in the U.S. will not significantly enhance the prospects of its CDMO unit; the risk that the Company will otherwise be unable to  remain compliant with the continued listing requirements of Nasdaq; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Photo - https://mma.prnewswire.com/media/2591208/Scinai_Immunotherapeutics.jpg
Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-to-connect-with-investors-and-pharma-leaders-at-upcoming-key-us-conferences-302342946.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What conferences will Scinai Immunotherapeutics (SCNI) attend in January 2025?

Scinai will attend three conferences: the IATI Mini Mixiii Conference in Miami on January 9, the JP Morgan HealthCare Conference in San Francisco from January 13-15, and the SIC Biotech Symposium in San Francisco on January 14, 2025.

Who will represent Scinai (SCNI) at the January 2025 healthcare conferences?

CEO Amir Reichman and Chairman of the Board Mark Germain will represent Scinai at the conferences.

What are the main objectives of Scinai's (SCNI) conference meetings in January 2025?

Scinai aims to meet with institutional and private investors, potential pharma partners interested in NanoAbs co-development or licensing, and prospective CDMO services clients.

How can interested parties schedule meetings with Scinai (SCNI) during the January 2025 conferences?

Meetings can be scheduled through the Mini Mixiii conference partnering platform, the CSSi partnering system, or by emailing ir@scinai.com.